Converting Enzyme Inhibitors Differentially Affect Expression of Genes of the Renin-Angiotensin System

References

• Jin M, Wilhelm M J, Lang R E, Unger T, Lindpaintner K, Ganten D. Endogenous tissue renin-angiotensin systems: From molecular biology to therapy. Am J Med 1988; 84(suppl 3A)28–36
   PubMedGoogle Scholar
• Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: An appraisal of present experimental and clinical evidence. Circ Res 1991; 68: 905–21
   PubMed Web of Science ®Google Scholar
• Mann J FE, Phillips M I, Dietz R, Haebara H, Ganten D. Effects of central and peripheral angiotensin blockade in hypertensive rats. Am J Physiol 1978; 234: H629–37
   PubMed Web of Science ®Google Scholar
• Xiang J Z, Linz W, Becker H, et al. Effects of converting enzyme inhibitors: Ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. Eur J Pharmacol 1984; 113: 215–23
   Web of Science ®Google Scholar
• Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: A link to cardiovascular hypertrophy?. J Hypertens 1991; 9: 3–15
   PubMed Web of Science ®Google Scholar
• Aceto J F, Baker K M. Angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol 1990; 258: H806–13
   PubMed Web of Science ®Google Scholar
• Clozel J P, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989; 7: 267–75
   PubMed Web of Science ®Google Scholar
• Jespersen L T, Nyborg N CP, Pedersen O L, Mikkelsen E O, Mulvany M J. Cardiac mass and peripheral vascular structure in hydralazine-treated spontaneously hypertensive rats. Hypertension 1985; 7: 734–41
   PubMed Web of Science ®Google Scholar
• Holck M, Fischli W, Hefti F, Gerold M. Cardiovascular effects of the new angiotensin-converting enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. J Cardiovasc Pharmacol 1986; 8: 99–108
   PubMed Web of Science ®Google Scholar
• Waeber B, Nussberger J, Brunner H R. Angiotensin-converting enzyme inhibitors in hypertension. Hypertension -Pathophysiology, Diagnosis and Management., J H Laragh, B M Brenner. Raven Press, New York 1990; 2209–23
   Google Scholar
• Unger T, Yukimura T, Marin-Grez M, Lang R E, Rascher W, Ganten D. SA446, a new orally active converting enzyme inhibitor: Antihypertensive action and comparison with captopril in stroke-prone spontaneously hypertensive rats. Eur J Pharmacol 1982; 78: 411–20
   PubMed Web of Science ®Google Scholar
• Unger T, Ganten D, Lang R E. Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J Cardiovasc Pharmacol 1986; 8(suppl 10)76–81
   Google Scholar
• Mall G, Mattfeldt T, Möbius H J, Leonhard R. Stereological study on the rat heart in chronic alimentary thiamine deficiency - Absence of myocardial changes despite starvation. J Mol Cell Cardiol 1986; 18: 635–43
   PubMed Web of Science ®Google Scholar
• di Sant'Agnese P A, de Mesy Jensen K L. Dibasic staining of large epoxy sections and applications to surgical pathology. Am J Clin Pathol 1984; 80: 25–9
   Google Scholar
• Unger T, Schüll B, Rascher W, Lang R E, Ganten D. Selective activation of the converting enzyme inhibitor MK421 and comparison of its active diacide form with captopril in different tissues of the rat. Biochemical Pharmacology 1982; 19: 3063–3070
   Google Scholar
• Auffray C, Rougeon F. Purification of mouse immunoglobulin heavy chain mRNAs from total myeloma tumor RNA. Eur J Biochem 1980; 107: 303–14
   PubMedGoogle Scholar
• Le Muer M, Glanville N, Mandel J, Gerlinger P, Palmiter R, Chambon P. The ovalbumin gene family: Hormonal control of X and Y gene transcription and mRNA accumulation. Cell 1981; 23: 561–71
   PubMed Web of Science ®Google Scholar
• Moos M, Gallwitz D. Structure of two human beta-actin-related processed genes -One is located next to a simple repetitive sequence. EMBO J 1983; 2: 757–61
   PubMed Web of Science ®Google Scholar
• Melton D A, Krieg P A, Rebagliati M R, Maniatis T, Zinn K, Green M R. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res 1984; 12: 7053–6
   Google Scholar
• Suzuki F, Ludwig G, Hellmann W, et al. Renin gene expression in rat tissues: A new quantitative assay method for rat renin mRNA using synthetic cRNA. Clin Exp Hypertens (A) 1988; 10: 345–59
   PubMed Web of Science ®Google Scholar
• Hellmann W, Suzuki F, Ohkubo H, Nakanishi S, Ludwig G, Ganten D. Angiotensinogen gene expression in extrahepatic rat tissues: Application of a solution hybridization assay. Naunyn-Schmiedeberg's Arch Pharmacol 1988; 338: 327–31
   Google Scholar
• Mann J FE, Johnson A K, Ganten D. Plasma angiotensin II: Dipsogenic levels and angiotensin-gene-rating capacity of renin. Am J Physiol 1980; 238: R372–7
   PubMed Web of Science ®Google Scholar
• Hilgers K F, Kuczera M, Wilhelm M J, Andrzej W, Ritz E, Ganten D. Angiotensin formation in the isolated rat hind limb. J Hypertens 1989; 7: 789–98
   PubMed Web of Science ®Google Scholar
• Thurston H, Swales J D. Blood pressure response of nephrectomized hypertensive rats to converting enzyme inhibition: Evidence for persistent vascular renin activity. Clin Sci Mol Med 1977; 52: 299–304
   PubMedGoogle Scholar
• Man in't Veld A J, Schicht I M, Derckx F AM, De Bruyn J HB, Schalekamp M ADH. Effects of angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. BMJ 1980; 1: 288–90
   Google Scholar
• Mullins J J, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344: 541–4
   PubMed Web of Science ®Google Scholar
• Garanin G. A comparison of once-daily antihypertensive therapy with captopril and enalapril. Curr Ther Res 1986; 40: 567–75
   Web of Science ®Google Scholar
• De Cesaris R, Ranieri G, Salzano E V, Liberatore S M. Once-daily therapy with angiotensinogen converting enzyme inhibitors in mild hypertension: A comparison of captopril and enalapril. J Hypertens 1987; 5(suppl 5)595–7
   Google Scholar
• Schoenberger J A, Wilson D J. Once-daily treatment of essential hypertension with captopril. J Clin Hypertens 1986; 4: 379–87
   Google Scholar
• Linz W, Schölkens B A, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens (A) 1989; 11: 1325–50
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Urata H, Bumpus F M, Husain A. Measurement of angiotensin I converting enzyme inhibition in the heart. Circ Res 1993; 73: 51–60
   PubMed Web of Science ®Google Scholar
• Hirsch A T, Talsness C E, Smith A D, Schunkert H S, Ingelfinger J R, Dzau V J. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1993; 86: 1566–174
   Web of Science ®Google Scholar
• Beerman B. Pharmacokinetics of lisinopril. Am J Med 1988; 85: 25–30
   PubMed Web of Science ®Google Scholar
• Natoff I L, Nixon J S, Francis R J, et al. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril. J Cardiovasc Pharmacol 1985; 7: 569–80
   PubMed Web of Science ®Google Scholar
• Shionori H, Gotoh E, Takagi N. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function. J Cardiovasc Pharmacol 1988; 11: 242–9
   PubMed Web of Science ®Google Scholar
• Becker R HA, Schölkens B A, Metzger M, Schulze K J. Pharmacological properties of the new orally active angiotensin-converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0] octane-3-carboxylic acid (HOE498). Arzneim Forsch 1984; 34: 1411–6
   PubMed Web of Science ®Google Scholar
• Bünning P. Kinetic properties of the angiotensin-converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol 1987; 10(suppl 7)31–5
   Google Scholar